FCN1 Deficiency care technology platforms are the digital infrastructure supporting comprehensive management of FCN1 Deficiency — a primary innate immune disorder caused by pathogenic variants in the FCN1 gene on chromosome 9q34 encoding ficolin-1 (also called M-ficolin or ficolin-alpha), a pattern recognition molecule of the lectin complement pathway that is structurally homologous to ficolin-2 and ficolin-3 but uniquely expressed: while ficolin-2 and ficolin-3 are primarily secreted by the liver into the bloodstream as soluble serum lectins, ficolin-1 is expressed predominantly in monocytes, macrophages, and granulocytes of the bone marrow, and is found at high concentrations on the surface of monocytes and in intracellular vesicles of neutrophils, as well as in secretions including lung alveolar fluid and bronchial secretions. Ficolin-1 recognizes N-acetylglucosamine (GlcNAc), N-acetylmannosamine, acetylcholine, sialic acid, and additional acetylated ligands on the surface of bacteria and apoptotic cells through its fibrinogen-like recognition domain, and associates with MASP-2 to form complexes capable of activating the lectin complement pathway on pathogen and apoptotic cell surfaces — providing an intracellular and secretory pattern recognition function that complements the serum-based opsonization function of ficolin-2 and ficolin-3. The FCN1 gene is located on chromosome 9q34.3, in close proximity to FCN2 (encoding ficolin-2) and within the broader complement regulatory gene cluster; copy number variation, promoter polymorphisms, and rare coding variants in FCN1 can reduce ficolin-1 surface expression on monocytes, diminish secretory ficolin-1 in alveolar lavage fluid, and impair complement activation on bacterially contaminated surfaces in the respiratory and gastrointestinal tracts. Clinical associations of FCN1 deficiency include increased susceptibility to respiratory infections, systemic lupus erythematosus (SLE) and lupus nephritis, inflammatory bowel disease (where ficolin-1 may contribute to mucosal complement defense), sepsis susceptibility, and modulation of response to infections with intracellular pathogens where monocyte-expressed ficolin-1 may contribute to phagocytic recognition and killing. Care platforms supporting FCN1 deficiency patients must coordinate ficolin-1 and lectin pathway biomarker surveillance (monocyte surface ficolin-1 expression by flow cytometry, serum ficolin-1 antigen if measurable, lectin pathway functional composite assays, MASP-2 levels, parallel ficolin-2 and ficolin-3 assessments to evaluate overall lectin pathway competence), respiratory infection tracking and pulmonary function monitoring, autoimmune disease surveillance for SLE and inflammatory conditions, and multidisciplinary specialist coordination across clinical immunology, pulmonology, infectious disease, rheumatology, and gastroenterology — all depending on continuous, verified platform availability.
This guide covers what FCN1 Deficiency care technology platforms need to monitor, why continuous availability matters across the spectrum of FCN1 Deficiency — from lectin complement pathway impairment through intracellular and secretory ficolin-1 loss to respiratory infection susceptibility, autoimmune predisposition, and inflammatory bowel disease complications, and how to build a monitoring strategy that protects the lectin pathway biomarker surveillance, respiratory infection management, autoimmune and inflammatory disease monitoring, and emergency escalation workflows that FCN1 Deficiency management requires.
Why FCN1 Deficiency Care Tech Platforms Cannot Afford Downtime
FCN1 Deficiency management is built on four pillars: lectin pathway and ficolin-1 biomarker surveillance (monocyte surface ficolin-1 expression by flow cytometry as the primary functional measure of FCN1 deficiency, serum ficolin-1 antigen levels where measurable, bronchoalveolar lavage ficolin-1 measurement in patients with recurrent pulmonary infections, composite lectin pathway functional assay, MASP-2 antigen and activity, ficolin-2 and ficolin-3 serum antigen and function to assess residual lectin pathway capacity, MBL antigen and function, CH50 and AH50 for overall complement integrity), respiratory infection management and pulmonary surveillance (antibiotic prophylaxis coordination, pulmonary function monitoring for bronchiectasis and airway disease, vaccination management for respiratory pathogens, sputum culture tracking, chest CT coordination), autoimmune and inflammatory disease management (ANA panel, anti-dsDNA, complement consumption, SLEDAI scoring for SLE surveillance; fecal calprotectin, colonoscopy coordination, and biologic therapy management for inflammatory bowel disease), and multidisciplinary specialist coordination. The platforms supporting FCN1 deficiency programs must remain continuously available — because respiratory infections, SLE flares, and inflammatory bowel disease exacerbations represent the primary sources of morbidity in ficolin-1 deficiency and require continuous monitoring and rapid specialist response.
Ficolin-1 occupies a unique immunological niche as a monocyte-expressed and secretory lectin: unlike ficolin-2 and ficolin-3 that circulate as serum complement activators targeting blood-borne pathogens and systemic immune complexes, ficolin-1 functions at epithelial surfaces and within the monocyte-macrophage compartment to recognize and opsonize pathogens at the point of entry. In the lung, alveolar ficolin-1 in secretory fluid provides immediate complement activation on inhaled bacterial and fungal surfaces before blood-borne ficolin-2 and systemic complement can be recruited — FCN1-deficient individuals therefore lack this critical first-line mucosal complement defense layer in the respiratory tract. Digital platforms tracking respiratory infection frequency and severity, alveolar lavage ficolin-1 levels in patients with recurrent pneumonia, pulmonary function trajectories, and antibiotic prophylaxis compliance must be available 24/7 to detect the early bronchiectasis development that indicates inadequate infection control in this first-line mucosal defense-deficient state.
The association between FCN1 deficiency and SLE appears to operate through impaired monocyte-mediated phagocytic clearance of apoptotic cells: ficolin-1 expressed on the monocyte surface acts as an opsonin receptor that recognizes N-acetylglucosamine and sialic acid residues on the outer leaflet of apoptotic cell membranes (where phosphatidylserine flip-flop also exposes these modified saccharides), facilitating efferocytosis — the anti-inflammatory engulfment of apoptotic cells that prevents their secondary necrosis and release of nuclear antigens. FCN1-deficient monocytes have reduced capacity for ficolin-1-mediated apoptotic recognition, contributing to impaired efferocytosis, accumulation of secondary necrotic debris, exposure of nuclear antigens to dendritic cells and B cells, and generation of the anti-nuclear and anti-dsDNA autoantibody responses that define SLE. Platforms tracking ANA titers, anti-dsDNA levels, complement C3 and C4 consumption during SLE flares, SLEDAI disease activity scores, and hydroxychloroquine and immunosuppressive medication management must remain continuously available for FCN1-deficient SLE patients who face both the primary immunodeficiency complications and the autoimmune disease management burden simultaneously.
Emerging evidence associates FCN1 polymorphisms with inflammatory bowel disease (Crohn's disease and ulcerative colitis) susceptibility through impairment of mucosal complement activation against gut microbiota and bacterial translocation: ficolin-1 expressed by lamina propria macrophages may contribute to complement-mediated recognition and clearance of bacteria that breach the intestinal epithelial barrier, and FCN1 deficiency may impair this response, contributing to dysregulated mucosal inflammation and IBD pathogenesis. FCN1-deficient patients with coexisting IBD require coordinated care platforms tracking fecal calprotectin and lactoferrin for IBD activity monitoring, colonoscopy scheduling and biologic therapy (anti-TNF, vedolizumab, ustekinumab) management — platforms that must be continuously available because IBD exacerbations requiring dose adjustment or escalation of biologic therapy can occur rapidly and require timely specialist access.
What to Monitor on a FCN1 Deficiency Care Tech Platform
Lectin Pathway and Ficolin-1 Biomarker Surveillance Dashboard
Monitor the lectin pathway and ficolin-1 biomarker tracking portal (monocyte surface ficolin-1 expression by flow cytometry using anti-FCN1 monoclonal antibody — the primary functional measure of FCN1 deficiency, serum ficolin-1 antigen by ELISA where available, bronchoalveolar lavage ficolin-1 levels in pulmonary disease patients, MASP-2 antigen and serine protease activity, ficolin-2 antigen and functional complement activation assay, ficolin-3 antigen and activity, MBL antigen and functional assay, composite lectin pathway complement activation on GlcNAc-acetylated substrate, CH50 classical pathway hemolytic activity, AH50 alternative pathway hemolytic activity, C3 and C4 as overall complement consumption markers, and FCN1 gene variant documentation with predicted functional impact and minor allele frequency) — at a 1-minute interval. Because ficolin-1 is primarily cell-associated rather than serum-based, laboratory assessment requires dedicated flow cytometric immunophenotyping of peripheral blood monocytes; coordination of these specialized assays through a continuously available platform is essential for monitoring changes in monocyte ficolin-1 expression during acute infection, immunosuppressive therapy, or disease course changes.
Respiratory Infection Management and Pulmonology Platform
Monitor the pulmonology co-management portal, respiratory infection episode frequency and severity documentation (pneumonia, bronchitis, sinobronchial syndrome tracking with causative organism, antibiotic response, and hospitalization data), pulmonary function testing scheduling and trend analysis (FEV1, FVC, FEV1/FVC ratio, diffusing capacity for early bronchiectasis and airway disease detection), antibiotic prophylaxis management portal (prophylactic azithromycin, amoxicillin-clavulanate, or inhaled tobramycin for bronchiectasis maintenance depending on colonizing organisms), sputum microbiology result delivery (Pseudomonas aeruginosa, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and nontuberculous mycobacteria in chronic bronchiectasis), high-resolution chest CT imaging scheduling and bronchiectasis progression scoring, bronchoscopy and bronchoalveolar lavage coordination, vaccination status tracking (PCV15/PCV20, PPSV23, MenACWY, MenB, annual influenza, COVID-19), and pulmonary rehabilitation coordination — at a 1-minute interval. Pulmonary function decline and bronchiectasis progression are the primary long-term morbidity drivers in FCN1-deficient patients with recurrent respiratory infections; uninterrupted platform access for spirometry scheduling, sputum surveillance, and antibiotic prophylaxis compliance is essential for preserving lung function over the decades-long management horizon.
Autoimmune Disease Surveillance and Rheumatology Platform
Monitor the autoimmune disease screening and management portal, antinuclear antibody (ANA) panel result delivery (anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-ribosomal P, anti-histone as SLE markers), complement consumption monitoring (C3 and C4 falling in active SLE, C4 specifically consumed by classical pathway activation from immune complex deposition), SLEDAI-2K disease activity scoring interface, renal function monitoring for lupus nephritis surveillance (urine protein-to-creatinine ratio, urinalysis for RBC casts, serum creatinine and eGFR), hydroxychloroquine blood level monitoring, immunosuppressive medication management portal (mycophenolate, azathioprine, belimumab, anifrolumab, rituximab), antiphospholipid antibody panel (lupus anticoagulant, anticardiolipin, anti-β2GP1), and rheumatology and nephrology consultation scheduling — at a 2-minute interval. SLE in FCN1-deficient patients may present earlier, with more severe lupus nephritis, and with a more refractory course than in immunologically intact SLE patients because the underlying efferocytosis defect maintains the autoantigen exposure that drives autoimmunity; comprehensive SLE disease activity monitoring with uninterrupted platform access is essential for detecting the nephritis flares and extrarenal complications that determine long-term SLE prognosis.
Inflammatory Bowel Disease Monitoring and Gastroenterology Platform
Monitor the gastroenterology co-management portal, fecal calprotectin and lactoferrin result delivery (validated biomarkers of intestinal inflammation that track IBD mucosal activity), colonoscopy and ileoscopy scheduling and endoscopic severity score result delivery, magnetic resonance enterography scheduling for small bowel Crohn's monitoring, biologic therapy management portal (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab dosing and trough level monitoring), biologic drug antibody level tracking, C-reactive protein and erythrocyte sedimentation rate trending for systemic inflammatory activity, stool culture and Clostridioides difficile testing coordination, and gastroenterology consultation scheduling — at a 2-minute interval. IBD exacerbations in FCN1-deficient patients may reflect compounded mucosal complement defense failure and IBD immunopathology; biologic therapy dose optimization and de-escalation decisions require regular fecal calprotectin and endoscopic monitoring that depends on continuous platform access, particularly in patients who face the additional infection risk of anti-TNF therapy on a background of innate immune deficiency.
Sepsis and Systemic Infection Surveillance Platform
Monitor the infectious disease co-management portal, systemic infection risk assessment dashboard (tracking neutropenia, immunosuppressive medication burden, and invasive procedure exposure as infection risk modifiers), blood culture result delivery, procalcitonin and C-reactive protein trending for early sepsis detection, body temperature trending interface, complete blood count with differential for neutrophil count monitoring, and emergency infectious disease consultation scheduling — at a 1-minute interval. FCN1-deficient patients on immunosuppression for SLE or IBD face compound infection risks from: the primary innate immune deficiency (impaired monocyte ficolin-1-mediated opsonization), the iatrogenic immunosuppression (corticosteroids, cytotoxics, anti-TNF agents reducing adaptive immune responses), and any biologic therapy-associated opportunistic infection risk. Real-time systemic infection surveillance through continuously available platforms enables early detection of the fever and laboratory markers that precede overt sepsis.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. FCN1-deficient patients presenting to emergency departments with acute respiratory decompensation, gastrointestinal hemorrhage from IBD, systemic sepsis on immunosuppression, or neurological symptoms of SLE require immediate provider access to their lectin pathway deficiency diagnosis, current prophylaxis and immunosuppressive regimen, pulmonary function trajectory, IBD disease activity history, and autoimmune disease status — EHR integration failures at emergency presentations cause clinically critical delays in immunodeficiency-aware triage and treatment.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures simultaneously lock clinical immunologists, pulmonologists, gastroenterologists, rheumatologists, nephrologists, and infectious disease specialists out of ficolin-1 biomarker dashboards, respiratory infection surveillance portals, IBD activity monitoring platforms, and autoimmune disease management systems — disabling the entire FCN1 deficiency digital management infrastructure at precisely the moment when a patient with acute respiratory failure, IBD hemorrhage, SLE nephritis flare, or sepsis requires immediate multi-specialist access.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains. FCN1 Deficiency care platforms handle sensitive innate immune deficiency biomarker data, respiratory infection and pulmonary function monitoring records, IBD disease activity surveillance data, autoimmune disease management records, and immunosuppressive medication monitoring results — certificate failures disrupt clinical integrations and patient portal access at moments when respiratory infection management, IBD monitoring, or SLE management may be clinically urgent.
Alerting Strategy for FCN1 Deficiency Care Tech Platforms
Immediate clinical escalation (24/7): Lectin pathway and ficolin-1 biomarker surveillance dashboard, respiratory infection management and pulmonology platform, sepsis and systemic infection surveillance platform, and emergency escalation infrastructure. FCN1 deficiency-associated respiratory infections and sepsis on immunosuppression do not observe business hours — acute respiratory deterioration or high fever with elevated procalcitonin in an FCN1-deficient patient on systemic immunosuppression requires immediate emergency escalation with immunodeficiency context available to treating clinicians.
Immediate clinical operations escalation: Autoimmune disease surveillance and rheumatology platform. Active SLE flares with rising anti-dsDNA titers, falling complement C3, or new proteinuria require same-day rheumatology and nephrology assessment; SLE nephritis flares in FCN1-deficient patients are particularly important to detect early because the underlying efferocytosis defect sustains the autoantigen drive that perpetuates nephritis.
High-priority clinical escalation: Inflammatory bowel disease monitoring and gastroenterology platform. Rapidly rising fecal calprotectin, rectal bleeding, or systemic inflammatory markers in an FCN1-deficient patient on biologic therapy require same-day or next-business-day gastroenterology assessment for IBD flare management, biologic dose escalation, or infectious complication evaluation.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
FCN1 deficiency patients face risks across respiratory infection, autoimmune disease (SLE), inflammatory bowel disease, and systemic infection on immunosuppression — requiring alert coverage across clinical immunology, pulmonology, rheumatology, nephrology, gastroenterology, and infectious disease on-call chains.
Status Page as a Clinical Safety Signal
FCN1 Deficiency care coordinators and on-call clinical immunologists managing after-hours contacts from patients or families reporting acute respiratory deterioration, high fever in an immunosuppressed patient, bloody diarrhea (IBD flare), or new joint pain and rash (SLE flare) need immediate platform status awareness before initiating escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from patient connectivity problems, and to initiate immediate phone-based emergency specialist consultation when the ficolin-1 surveillance or multi-system disease management platform is confirmed unavailable for a patient with suspected acute severe infection, IBD hemorrhage, or SLE nephritis episode.
For FCN1 deficiency programs coordinating respiratory infection prophylaxis, lectin complement pathway biomarker surveillance, autoimmune disease management, IBD activity monitoring, and systemic infection surveillance — a publicly accessible status page enables rapid identification of platform failures and activation of manual monitoring fallback protocols including direct emergency department contact, paper-based pulmonary function and respiratory infection documentation, manual IBD disease activity tracking, manual SLE disease activity scoring, and phone-based multi-specialist escalation chains. Publish the status page URL in on-call immunology, pulmonology, gastroenterology, rheumatology, and infectious disease provider handoff materials, patient family emergency contact instructions, and care coordinator shift briefing documents.
The Business Case: FCN1 Deficiency Management Quality and Program Outcomes
FCN1 deficiency programs operate in a management environment characterized by both the rarity and the emerging nature of the clinical phenotype: while FCN1 polymorphisms are known to associate with SLE, IBD, respiratory infections, and sepsis susceptibility in population studies, the clinical characterization of complete FCN1 deficiency as a specific primary immunodeficiency syndrome is still evolving — most FCN1-deficient patients are identified at specialized clinical immunology centers with expertise in lectin pathway assessment, and many will present through multidisciplinary pathways (rheumatology for SLE, gastroenterology for IBD, pulmonology for recurrent pneumonia) before the underlying innate immune deficiency is recognized. Once diagnosed, FCN1-deficient patients require coordinated multi-system care across respiratory, autoimmune, inflammatory, and infectious disease domains — a coordination burden that depends entirely on digital platforms maintaining continuous availability across all of these clinical interfaces simultaneously.
Health system clinical immunology, pulmonology, rheumatology, and gastroenterology programs managing FCN1 deficiency populations face regulatory oversight from Joint Commission standards requiring documented availability monitoring for clinical decision support systems, URAC standards for specialty pharmacy managing prophylactic antibiotics, biologics for IBD, and immunosuppressive agents for SLE, CMS conditions of participation for renal disease monitoring in lupus nephritis patients, and primary immunodeficiency accreditation requirements for centers providing care to patients with lectin pathway deficiencies. External monitoring from Vigilmon provides the documented, independent availability record that FCN1 Deficiency program directors can present to hospital administration, accreditation bodies, and rare disease program evaluators as evidence that lectin pathway biomarker surveillance and multi-system disease management platforms maintained the continuous availability required by primary innate immune deficiency care quality standards.
Vigilmon Setup for FCN1 Deficiency Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Lectin pathway / ficolin-1 biomarker surveillance dashboard | 1 min | PagerDuty (immediate, 24/7) | | Respiratory infection management / pulmonology platform | 1 min | PagerDuty (immediate, 24/7) | | Sepsis / systemic infection surveillance platform | 1 min | PagerDuty (immediate, 24/7) | | Autoimmune disease surveillance / rheumatology platform | 2 min | PagerDuty (immediate) | | Inflammatory bowel disease monitoring / gastroenterology platform | 2 min | PagerDuty (high-priority) | | EHR integration endpoint | 5 min | Slack + on-call email | | Authentication service | 1 min | PagerDuty (immediate, 24/7) | | SSL certificates (all domains) | 30-day advance | Slack + email |
Getting started:
- Create a free account at vigilmon.online
- Add the lectin complement pathway and ficolin-1 biomarker surveillance dashboard as your first 1-minute monitor — monocyte surface FCN1 expression by flow cytometry, ficolin-2 and ficolin-3 serum levels, MASP-2 activity, and composite lectin pathway functional assay data must be accessible 24/7 for on-call clinical immunologists managing FCN1-deficient patients with acute infection or autoimmune flare
- Add the respiratory infection management and pulmonology platform at 1-minute intervals with immediate PagerDuty escalation — respiratory infection frequency, pulmonary function trends, sputum microbiology, and antibiotic prophylaxis compliance require uninterrupted platform access to prevent the bronchiectasis progression that is the primary long-term morbidity in FCN1-deficient patients with recurrent pulmonary infections
- Add the sepsis and systemic infection surveillance platform at 1-minute intervals — procalcitonin trending, blood culture result delivery, and fever monitoring are essential for FCN1-deficient patients on systemic immunosuppression for SLE or IBD
- Add the autoimmune disease surveillance and rheumatology platform at 2-minute intervals — ANA panel trending, complement consumption monitoring, renal function surveillance for lupus nephritis, and SLE disease activity scoring guide immunosuppressive therapy escalation decisions
- Add the inflammatory bowel disease monitoring and gastroenterology platform at 2-minute intervals — fecal calprotectin, colonoscopy coordination, biologic therapy trough levels, and drug antibody monitoring require coordinated platform access for IBD flare management
- Add EHR integration, authentication, and all SSL certificates — configure 30-day advance certificate expiry alerts across every patient-facing and clinician-facing domain
Conclusion
FCN1 Deficiency care tech platforms hold the clinical surveillance infrastructure that makes modern ficolin-1 deficiency management possible — spanning real-time lectin complement pathway and ficolin-1 biomarker trending (monocyte surface FCN1 expression by flow cytometry, serum ficolin-1 antigen where available, bronchoalveolar lavage ficolin-1 in recurrent pulmonary disease patients, MASP-2 antigen and activity, ficolin-2 and ficolin-3 assessments for residual lectin pathway capacity, MBL, composite lectin pathway functional assay, CH50 and AH50 for overall complement integrity), respiratory infection management (pneumonia and bronchitis episode tracking with causative organism and antibiotic outcome documentation, antibiotic prophylaxis coordination, pulmonary function monitoring, high-resolution CT bronchiectasis staging, sputum microbiology surveillance, pulmonary rehabilitation coordination), autoimmune disease management (ANA and anti-dsDNA trending, complement consumption monitoring during SLE flares, SLEDAI scoring, lupus nephritis surveillance with urine protein and eGFR trending, hydroxychloroquine and mycophenolate/belimumab/anifrolumab management), inflammatory bowel disease monitoring (fecal calprotectin and lactoferrin trending, colonoscopy and MR enterography coordination, biologic therapy dosing and trough level optimization, drug antibody surveillance), systemic infection surveillance (procalcitonin and CRP trending, blood culture coordination, neutrophil count monitoring, sepsis early warning), emergency escalation for acute respiratory failure, IBD hemorrhage, sepsis on immunosuppression, and SLE nephritis flares, and telemedicine triage for the urgent symptom assessments — acute dyspnea, high fever in an immunosuppressed patient, rectal bleeding, new proteinuria — that may represent the earliest presentations of severe pneumonia, opportunistic infection, IBD hemorrhage, or SLE nephritis flare in an FCN1-deficient patient whose lectin complement pathway impairment at both the monocyte surface and the mucosal secretory layer creates compound vulnerability across respiratory, gastrointestinal, renal, and systemic infectious disease domains — all of which depend on continuous, verified platform availability from which any unmonitored gap creates clinical risk across the full multi-system disease spectrum of ficolin-1 innate immune deficiency.
External monitoring from Vigilmon provides the independent, outside-in availability view that FCN1 Deficiency program directors and health system IT teams need to catch platform failures before they affect ficolin-1 and lectin pathway surveillance, respiratory infection management, autoimmune and IBD disease monitoring, and emergency escalation workflows — with the documented incident record that accreditation bodies and rare disease program evaluators accept as evidence of operational maturity.
Start monitoring your FCN1 Deficiency care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #fcn1deficiency #ficolin1 #mficolin #lectinpathway #complementdeficiency #masp2 #respiratoryinfections #bronchiectasis #sle #lupusnephritis #inflammatoryboweldisease #primaryimmunodeficiency #innateimmunity #healthtech #uptime #clinicaldocumentation #sre